Skip to Content

Fresenius Medical Care AG ADR

FMS: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$99.00ZsnqnmQyq

Fresenius Medical Care Earnings: Strong End to 2023, but Light 2024 Guidance Keeps Our FVE Intact

Narrow-moat Fresenius Medical Care turned in solid fourth-quarter results and exceeded our profit expectations for the full year, but 2024 guidance was a bit lighter than we were anticipating. Overall, though, we do not anticipate changing our fair value estimate, which remains well above recent trades.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of FMS so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center